Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
mean decrease » a decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
Showing 1,041 - 1,060 results of 44,763 for search '(( a ((nn decrease) OR (mean decrease)) ) OR ( i ((largest decrease) OR (larger decrease)) ))', query time: 0.86s Refine Results
  1. 1041
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  2. 1042
    Mean value of the longitudinal scaling exponent as a function of the growth rate threshold <i>b</i><sub><i>c</i></sub>.

    Mean value of the longitudinal scaling exponent as a function of the growth rate threshold <i>b</i><sub><i>c</i></sub>. by Fabiano L. Ribeiro (4893388)

    Published 2020
    “…The mean value of decreases drastically as <i>b</i><sub><i>c</i></sub> increases. …”
    Save to List
    Saved in:
  3. 1043
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 1044
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  5. 1045
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 1046
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 1047
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 1048
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 1049
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 1050
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 1051
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 1052
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 1053
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 1054
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 1055
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 1056
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 1057
    Estimated marginal means for changes in outcome parameters A, B, C, D.

    Estimated marginal means for changes in outcome parameters A, B, C, D. by Benjamin Udoka Nwosu (476930)

    Published 2015
    Save to List
    Saved in:
  18. 1058
    <i>In vivo</i> and long-term chaperone activity assessment of wild-type and p.R163C mutant αB-crystallin.

    <i>In vivo</i> and long-term chaperone activity assessment of wild-type and p.R163C mutant αB-crystallin. by Aref Baharvand (21713886)

    Published 2025
    Save to List
    Saved in:
  19. 1059
    RNA Interference in <em>Schistosoma mansoni</em> Schistosomula: Selectivity, Sensitivity and Operation for Larger-Scale Screening

    RNA Interference in <em>Schistosoma mansoni</em> Schistosomula: Selectivity, Sensitivity and Operation for Larger-Scale Screening by Saša Štefanić (239531)

    Published 2010
    “…These findings and the operational parameters defined will facilitate larger RNAi screens.</p></div>…”
    Save to List
    Saved in:
  20. 1060
    S1 File -

    S1 File - by Yashengnan Sun (12501626)

    Published 2022
    Save to List
    Saved in:

Search Tools: